We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Digoxin

News List

C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19 Combination Treatment C2 PHARMA
March 27, 2020
C2 PHARMA s.a.r.l. (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin.
C2 PHARMA Continues to Expand API Portfolio with Digoxin Micronized Grade, Homatropine Hydrobromide and Multiple Products Under Tech Transfer and Development En-CPhI.CN
November 06, 2019
C2 PHARMA s.a.r.l. (C2P) continues to build its active pharmaceutical ingredient (API) and botanical extracts product portfolio.